Grünenthal Group selects Dotmatics' data query, analysis and visualization suite for Discovery research scientists

BISHOPS STORTFORD, England -- Dotmatics Limited, a leading provider of scientific information management solutions announced today that Grünenthal the Group, a leading pharmaceutical company with headquarters in Germany, selected its state-of-the-art enterprise informatics solutions after a rigorous tender process and evaluating various vendors.

Dotmatics' Vortex is a world-class visualization and analytics platform for scientific data. It includes the ability to create and manipulate plots, calculate properties and filter as well as profile compounds.Browser is a flexible query and visualization tool for biological and chemical datasets alike. It allows the search of multiple data formats and includes a variety of reporting tools. Both tools are designed to facilitate the discovery process, thus increasing the overall output of research organizations.

"In 2010, we started a detailed evaluation of various informatics solutions that would provide us with optimal support to query, report, and analyse our complex chemical and biological data. The powerful interplay between Browser's ability to query and retrieve information and Vortex' data analysis, visualisation, and reporting proved to be the most flexible solution for supporting our multidisciplinary project teams" said Dr. Henning Steinhagen - Senior Vice President Global Drug Discovery, GrünenthalGroup. "We expect that research collaboration as well as overall efficiency and productivity at Grünenthal will be increased by implementing Browser and Vortex" he added.

"We are pleased that Grünenthal has chosen Dotmatics' Vortex and Browser as their platform for data management and analysis" said Steve Gallagher – CEO of Dotmatics. "Vortex and Browser are the result of many years of listening to what the biotech and pharmaceutical industry needed to improve productivity. We are working closely with our customers to deliver solutions that fulfil their requirements. Our commitment to quality software and customer satisfaction is leading our company to rapidly become the industry standard for scientific data management and analysis".

About Dotmatics

Dotmatics has rapidly emerged as a preferred informatics supplier to many of the top global pharmaceutical, biotechnology, and academic organisations. Dotmatics is a scientific software company deploying web-based knowledge solutions that dramatically improve the way scientific data is queried, managed and shared within companies. Dotmatics has significant expertise in chem- and bioinformatics techniques including chemical databases, SAR analysis, data management and data visualization. A privately owned company, Dotmatics was founded in 2005 and has its head office based south of Cambridge, UK.

About Grünenthal

The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation.

Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 26 percent of revenues in 2012. Grünenthal's research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.

Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of €973 mn.

More information:


Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.